MYGN Myriad Genetics, Inc.
Healthcare$3.85+0.79%ClosedMarket Cap: $363.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.06
P/S
0.44
EV/EBITDA
-1.34
DCF Value
$-20.29
FCF Yield
-5.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.0%
Operating Margin
-46.3%
Net Margin
-48.2%
ROE
-109.1%
ROA
-59.4%
ROIC
-69.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $200.4M | 68.7% | $-25.3M | $-34.1M | $— | — |
| Q4 null | $209.8M | 70.0% | $-5.7M | $-7.9M | $— | — |
| FY null | $824.5M | 69.9% | $-67.8M | $-365.9M | $— | — |
| Q3 null | $205.7M | 69.9% | $-23.3M | $-27.4M | $— | — |
| Q2 null | $213.1M | 71.2% | $-329.2M | $-330.5M | $— | — |
| Q1 null | $195.9M | 68.5% | $-29.0M | $-100.0K | $— | — |
| Q4 null | $210.6M | 71.7% | $-39.0M | $-42.5M | $— | — |
| FY null | $837.6M | 69.9% | $-123.5M | $-127.3M | $— | — |
| Q3 null | $213.3M | 70.2% | $-20.0M | $-22.1M | $— | — |
| Q2 null | $211.5M | 69.6% | $-36.5M | $-36.7M | $— | — |
| Q1 null | $202.2M | 68.1% | $-27.9M | $-26.0M | $— | — |
| Q4 2023 | $196.6M | 68.7% | $-31.4M | $-31.2M | $-0.36 | — |